Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

FATE Feb 2023 20.000 call

OPR - OPR Delayed Price. Currency in USD
5.680.00 (0.00%)
As of 01:19PM EST. Market open.
Advertisement
Full screen
Previous Close5.68
Open5.68
Bid2.25
Ask3.70
Strike20.00
Expire Date2023-02-17
Day's Range5.68 - 5.68
Contract RangeN/A
Volume5
Open Interest9
  • Insider Monkey

    9 Cheap Stocks to Buy According to Cathie Wood

    In this article, we discuss the 9 cheap stocks to buy according to Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to 4 Cheap Stocks to Buy According to Cathie Wood. Cathie Wood’s hedge fund ARK Investment Management has been battered this year as investors exit growth stocks […]

  • GlobeNewswire

    Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors

    Multiplexed-engineered, iPSC-derived CAR T-cell Product Candidate Demonstrated Broad, Potent and Specific CAR Activity Across Multiple Preclinical Solid Tumor Models Fate and ONO to Jointly Develop and Commercialize FT825/ONO-8250 in U.S. and Europe with ONO having Exclusive Rights in Rest of World SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for

  • GlobeNewswire

    Fate Therapeutics to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences: Cowen’s 6th Annual IO Next Summit available on demand on Friday, November 11, 2022 at 2:10 PM ETJefferies London Healthcare Conference on Wednesd

Advertisement
Advertisement